Virus-associated hemophagocytic syndrome (VAHS) is a severe and potentially life-threatening condition characterized by macrophage activation and hypercytokine state that leads to polyhematological disorders, including hemolytic anemia, thrombocytopenia, and liver disease. This syndrome is most often associated with viral infections such as Epstein-Barr virus, influenza virus, cytomegalovirus, and others. VAHS can develop both in the context of a primary infectious process and against the background of recurrent or chronic diseases, which complicates its diagnostic and therapeutic management. Without timely and adequate treatment, it can lead to multiorgan failure and a fatal outcome.
History of the disease and interesting historical facts
Hemophagocytic macrophage syndrome was first described in 1939 by physicians studying cases in which hemophagocytic reactions were observed in the bone marrow. However, a full understanding of the mechanisms associated with viruses and hemophagocytic hyperreaction developed gradually. In 1991, the concept of virus-associated hemophagocytic syndrome was developed when it became apparent that various viruses could initiate excessive activation of macrophages, leading to a systemic inflammatory response. In recent decades, VAHS has gained greater notoriety due to the increase in cases associated with Epstein-Barr virus-related infections.
Epidemiology
Virus-associated hemophagocytic syndrome is a relatively rare condition, but its incidence is increasing in line with the increasing number of viral infections. According to various studies, the incidence varies from 0.2 to 3.6 cases per 100,000 population per year. VAHS is more common in children, especially with Epstein-Barr virus-related infections, where it is diagnosed in approximately 5% cases of infectious mononucleosis. In adults, the figure is somewhat lower, but still significant; according to some data, VAHS occurs in 10-30% patients with acute infections caused by cytomegalovirus and influenza virus.
Genetic predisposition to this disease
At the genetic level, VAGS may be associated with certain mutations and polymorphisms affecting immune mechanisms. It has been found that the carriage of certain alleles of HLA genes, as well as mutations in genes associated with the response to infections, increases the risk of developing the syndrome. For example, mutations in genes encoding cytokines and their receptors (IL-10, IL-6, TNF-α) can contribute to excessive activation of macrophages. Cases of autosomal recessive hemophagocytic syndrome associated with genetic defects in the mechanisms of cell destruction have also been described.
Risk factors for the development of this disease
Among the risk factors that contribute to the development of virus-associated hemophagocytic syndrome, the following can be distinguished:
- Possible viral infectious agents such as Epstein-Barr virus, cytomegalovirus and others.
- Immunodeficiency states, including HIV infection.
- Some therapies aimed at suppressing the immune response.
- Hereditary factors predisposing to abnormalities in the immune system.
- Previous blood diseases and cancer.
Diagnosis of this disease
Diagnosis of VAGS is based on clinical, laboratory and radiological data. The main symptoms include:
- Fever, often with a high rise in temperature.
- Hemolytic anemia, detected by a decrease in hemoglobin levels and an increase in bilirubin levels.
- Thrombocytopenia and leukopenia.
- Symptoms of liver dysfunction, including enlargement of the liver and spleen.
Laboratory tests include:
- Complete blood count to detect anemia and thrombocytopenia.
- Blood biochemistry to assess liver function.
- Immunological studies to determine the level of cytokines and specific antibodies.
Radiologic studies may be used to visualize enlarged lymph nodes or other manifestations of disease. Differential diagnosis should include other conditions such as sepsis, systemic lupus erythematosus, and lymphomas.
Treatment
Treatment of VAGS requires a comprehensive approach and may include:
- General treatment: creating conditions to reduce temperature and maintain homeostasis.
- Pharmacological treatment: use of glucocorticoids and immunosuppressive agents to reduce the immune response.
- Surgical treatment: In rare cases, surgery may be required to remove the source of infection.
- Other treatments may include plasmapheresis and biological therapies such as anti-cytokine antibodies.
List of medications used to treat this disease
Among the medications used to treat VAGS, the following can be distinguished:
- Methylprednisolone.
- Dexamethasone.
- Cyclophosphamide.
- Rituximab.
- Tokilizumab (antibody to IL-6).
Disease monitoring
Disease control requires regular monitoring of the patient's condition and includes:
- Evaluation of full blood to determine the dynamics of anemia and thrombocytopenia.
- Monitoring liver function through biochemical tests.
- Assessment of clinical symptoms and general condition of the patient.
- The prognosis with adequate treatment is quite favorable, but there is a high probability of complications, such as infectious processes and organ failure.
Age-related features of the disease
VAGS may present differently in different age groups. In children, the condition is more often associated with infections such as infectious mononucleosis and presents with an acute onset and severe systemic symptoms. In adults, VAGS may develop against the background of chronic infections or blood diseases, and presents more covertly. Older patients may have a more complex course of the disease due to concomitant comorbid conditions.
Questions and Answers
- What are the main causes of virus-associated hemophagocytic syndrome? VAGS is often caused by viral infections such as Epstein-Barr virus and cytomegalovirus, but can also occur in the context of autoimmune diseases and systemic infections.
- What are the symptoms of this syndrome? The main symptoms include fever, hemolytic anemia, thrombocytopenia, and enlargement of the liver and spleen.
- How is this syndrome treated? Treatment includes glucocorticoids and other immunosuppressive agents. Biological agents may also be used.
- What are the possible complications if left untreated? Without treatment, VAGS can lead to multiple organ failure and a high risk of death.
- What is the prognosis for patients with VAGS? The prognosis depends on the speed of diagnosis and initiation of treatment; with adequate therapy, most patients can recover.
